Dr. John E. Thordsen JR., MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Ponce School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 821
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Ponce School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
NC license 2011-00308 -
Ophthalmology Physician
NC license 2011-00308
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Retina Associates, PLLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 821
- Services billed
- 23,939
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 13,080 | 19 |
| Injection, aflibercept, 1 mg | 3,312 | 211 |
| Injection of drug into eye | 1,930 | 308 |
| Imaging of retina | 1,511 | 358 |
| Photography of the retina | 1,319 | 783 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,178 | 677 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 890 | 23 |
| Injection, ranibizumab, 0.1 mg | 495 | 17 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 169 | 158 |
| Injection, bevacizumab, 10 mg | 168 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Raleigh, NC | 90 |
| Brimonidine Tartrate Other prescribers in Raleigh, NC | 70 |
| Prednisolone Acetate Other prescribers in Raleigh, NC | 57 |
| Tobramycin | 38 |
| Timolol Maleate Other prescribers in Raleigh, NC | 33 |
| Ketorolac Tromethamine Other prescribers in Raleigh, NC | 23 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Raleigh, NC | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $1,994 in total to this clinician.
| Ocular Therapeutix, Inc. | $1,600 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $228 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $111 |
| AbbVie Inc. | $35.21 |
| Lemaitre Vascular, Inc. | $19.53 |
| Consulting Fee | $1,600 |
|---|---|
| Food and Beverage | $394 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ocular Therapeutix, Inc. Nov 13, 2025 | Consulting Fee | $1,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $2,144,441 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema
Boehringer Ingelheim International GmbH - A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.